HCW Biologics Inc. HCWB
1.93
(0.06)
(3.02%)
as of 25 Sep
- Market cap
- $4.2M
- P/E
- 0.0×
Follow HCWB
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
19.81 | 37.55 | 0.30 | 0.99 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.58) | (0.61) | (1.24) | (1.67) | |
P/B ratio |
0.00 | 0.74 | 0.34 | 0.89 | |
Price to Tangible BV |
0.00 | 0.74 | 0.34 | 0.89 | |
EV/Sales |
34.21 | 133.75 | 1.16 | 1.91 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.12) | (0.54) | (0.67) | (1.06) | |
EV/FCF |
(1.10) | (0.53) | (0.65) | (1.03) | |
Quick Ratio |
0.04 | 0.09 | 0.07 | 0.04 | |
Current Ratio |
0.06 | 0.11 | 0.09 | 0.06 | |
Net Debt/EBITDA |
(1.83) | (1.13) | 1.58 | (1.91) | |
Debt/Assets |
26.75% | 27.77% | 24.06% | 24.51% | |
Debt/Equity |
(3.23) | 2.46 | 1.14 | 0.88 | |
Asset Turnover |
0.02 | 0.00 | 0.25 | 0.24 | |
Operating CF/Net income |
0.71 | 0.97 | (1.25) | 0.26 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9,001.28% | 4,937.41% | 19.23% | 887.46% | |
Selling, General and Administrative Expense of Revenue |
12,083.33% | 5,528.52% | 28.02% | 1,379.35% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,317.31% | 34.07% | 0.15% | 0.88% | |
Graham Net Nets |
(3.10) | (9.55) | (10.17) | (2.75) | |
Graham Number |
102.73 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(377.74%) | (1,214.07%) | (2,627.28%) | (553.05%) | |
Free Cash Flow Yield |
(157.04%) | (669.68%) | (599.93%) | (187.10%) | |
Revenue per Share |
0.04 | 0.08 | 7.24 | 0.10 | |
Operating CF per Share |
(8.60) | (9.60) | (1.74) | (2.99) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(8.60) | (9.60) | (1.74) | (2.99) | |
Cash per Share |
2.91 | 5.58 | 1.36 | 0.56 | |
Shareholders Equity per Share |
(5.59) | 7.91 | 6.37 | 5.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(5.59) | 7.91 | 6.37 | 5.59 | |
Free Cash Flow |
(3.24) | (3.36) | (1.58) | (3.97) | |
Working Capital |
(25.27) | (18.78) | (18.24) | (17.51) | |
Net Current Asset Value |
(25.96) | (19.47) | (19.86) | (18.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(29,194.23%) | (12,837.04%) | 19.19% | (11,337.68%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.34 | 0.31 | 0.08 | 0.02 | |
Average Payables |
20.82 | 17.74 | 15.76 | 14.98 | |
Average Assets |
26.00 | 27.38 | 26.81 | 27.84 | |
Average Common Equity |
(6.04) | (2.00) | (1.40) | 3.69 |
Columns are period end dates